M. Davis

发表

Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.

E. Emini, A. Gurtman, R. Frenck, 2016, Vaccine.

Immunogenicity and Safety of NVX-CoV2373 as a Homologous or Heterologous Booster: A Phase 3 Randomized Clinical Trial in Adults

F. Raiser, J. Plested, L. Dunkle, 2023, medRxiv.

Evaluation of the long-term safety of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo

K. Reape, H. Hait, M. Davis, 2007 .

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

I. Frank, P. Goepfert, S. Gurunathan, 2021, The Lancet Infectious Diseases.

Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.

R. Hopkins, E. Sheldon, Cynthia B Strout, 2014, Vaccine.

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.

R. Janssen, K. Reisinger, W. Heyward, 2013, Vaccine.

Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.

D. Vaughn, Ping Li, L. Fries, 2012, The Journal of infectious diseases.

A look at the long-term safety of an extended-regimen OC.

K. Reape, H. Hait, M. Davis, 2010, Journal of Family Practice.

Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins

Langzhou Song, L. Tussey, Ge Liu, 2016, Open forum infectious diseases.

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

E. Kerwin, J. Tica, F. Struyf, 2022, The Journal of infectious diseases.

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

E. Kerwin, J. Tica, N. Dezutter, 2020, Open Forum Infectious Diseases.